SAB Biotherapeutics (SABS) Current Deferred Revenue (2020 - 2024)
SAB Biotherapeutics' (SABS) quarterly Current Deferred Revenue came in at $114698.0 in Q3 2024, down 92.95% YoY from $1.6 million in Q4 2023, and little changed on a QoQ basis from $114698.0 in Q2 2024.
SAB Biotherapeutics (SABS) Current Deferred Revenue (2020 - 2024) Analysis & Trends
SAB Biotherapeutics (SABS) has 4 years of Current Deferred Revenue data on file, last reported at $114698.0 in Q3 2024.
- Quarterly Current Deferred Revenue fell 92.95% year-over-year to $114698.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $114698.0 (down 92.95% YoY) and the FY2023 annual result came in at $1.3 million, changed N/A from the prior year.
- Current Deferred Revenue held at $114698.0 in Q3 2024, from $114698.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $2.9 million in Q1 2023 to a low of $100000.0 in Q4 2020.
- A 4-year average of $1.1 million and a median of $377835.0 in 2024 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue changed 0.0% — and 2024, when it slumped 96.04%.
- Tracing SABS's Current Deferred Revenue over 4 years: stood at $100000.0 in 2020, then changed by 0.0% to $100000.0 in 2021, then surged by 1222.41% to $1.3 million in 2023, then sank by 91.33% to $114698.0 in 2024.
- The last three Current Deferred Revenue figures came in at $114698.0 (Q3 2024), $114698.0 (Q2 2024), and $377835.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 114,698.00 |
| Jun 30, 2024 | 114,698.00 |
| Mar 31, 2024 | 377,835.00 |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 2.89 Mn |
| Mar 31, 2023 | 2.94 Mn |
| Dec 31, 2021 | 100,000.00 |
| Dec 31, 2020 | 100,000.00 |